// App-Quantinova.ai

201 : Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Relapsed Myeloma: Long Term Follow up and Factors Predicing Outcome in 345 Patients

Researchers

Presenter

  • Shaji K. Kumar

Principal Investigators

  • Steven R Zeldenrust

  • Rafael Fonseca

  • P.Leif Bergsagel

  • Keith Stewart

  • Vivek Roy

  • Taimur Sher

  • Asher Chanan-Khan

  • Craig Reeder

  • S. Vincent Rajkumar

  • Joseph R. Mikhael

  • Kristina Laumann

  • Morie A Gertz

  • Suzanne R Hayman

  • Francis K Buadi

  • Angela Dispenzieri

  • John A. Lust

  • Stephen Russell

  • David Dingli

Medical Centers

  • Statistics, Mayo Clinic, Rochester, MN

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Deep vein thrombosis

  • Multiple Myeloma

  • Thrombocytopenia

  • Neutropenia

  • Venous thrombosis

  • Anemia

Biomarkers

  • beta-2 microglobulin

  • Lactate dehydrogenase

  • ZFP36 Ring Finger Protein Like 1

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Pomalidomide

  • CC-4047

  • Lenalidomide

  • Thalidomide

  • Bortezomib

  • Aspirin

  • Albyl-E

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved